Breaking News, Collaborations & Alliances

AstraZeneca, Heptares in Immuno-oncology Pact

Will develop novel immuno-oncology treatments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca and Heptares Therapeutics have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will explore the assets across a range of cancers, including in combination with its existing portfolio of immunotherapies. Heptares will grant AstraZene...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters